Ionis Pharmaceuticals (IONS) director reports 20,000-share family stock purchase
Rhea-AI Filing Summary
IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power. Genworks 2 acquired 15,000 shares on July 30, 2026 at a weighted-average price of $53.38 and 5,000 shares on July 31, 2026 at a weighted-average price of $51.60, for a total of 20,000 additional indirectly held shares. Hayden also reports direct ownership of 54,298 Ionis common shares.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 20,000 shares
Net Buy
3 txns
Insider
Hayden Michael R
Role
Director
Bought
20,000 shs ($1.06M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F3, F2 | 5,000 | $51.60 | $258K |
| Purchase | Common Stock F1, F2 | 15,000 | $53.38 | $801K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 24,000 shares (Indirect, by Spouse);
Common Stock — 54,298 shares (Direct)
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.
- F2. These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.
- F3. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4.
Key Figures
Shares purchased 2026-07-30: 15000 shares
Shares purchased 2026-07-31: 5000 shares
Weighted-average price 2026-07-30: $53.38 per share
+2 more
5 metrics
Shares purchased 2026-07-30
15000 shares
Indirect open-market purchase by Genworks 2 at weighted-average $53.38
Shares purchased 2026-07-31
5000 shares
Indirect open-market purchase by Genworks 2 at weighted-average $51.60
Weighted-average price 2026-07-30
$53.38 per share
Multiple trades with prices from $53.00 to $53.58 inclusive
Weighted-average price 2026-07-31
$51.60 per share
Multiple trades with prices from $51.45 to $51.70 inclusive
Direct holdings after transactions
54298 shares
Directly owned Ionis common stock as of July 30, 2026 holding entry
Key Terms
weighted average price, sole voting and investment power, indirect ownership, open market or private transaction
4 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
sole voting and investment power financial
"The Reporting Person's spouse has sole voting and investment power"
indirect ownership financial
"These securities are held by Genworks 2 Consulting, Inc."
open market or private transaction financial
"Purchase in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock purchases did Ionis Pharmaceuticals (IONS) disclose in this Form 4?
Ionis Pharmaceuticals reported that an entity associated with director Michael R. Hayden’s spouse bought 20,000 common shares in total, split between 15,000 shares on July 30, 2026 and 5,000 shares on July 31, 2026 in open-market transactions.
Were the Ionis (IONS) insider purchases made in a single trade or multiple trades?
Both reported purchases were executed as multiple trades. Footnotes explain that the prices shown are weighted averages, with individual trade prices ranging from $53.00 to $53.58 and from $51.45 to $51.70 for the respective transaction dates.